Optimal duration of allergic rhinitis clinical trials

John H. Krouse, Peter S. Roland, Bradley F. Marple, G. Michael Wall, Maureen Hannley, Suman Golla, Darrell Hunsaker

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

OBJECTIVE: Guidelines have been published by the Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA) for the conduct of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) studies. These guidelines have differences regarding the duration of such trials: the FDA suggests 2 weeks for SAR and 4 weeks for PAR but the EMEA suggests 2 to 4 weeks for SAR and 6 to 12 weeks for PAR trials. In the interest of global harmonization, it would be desirable to have a uniform duration of such trials so that investigators, internationally, would be able to readily compare results for various types of treatments based on a single standard. Therefore, we performed an evidence-based review to answer the clinical question, What is the optimal duration for SAR and PAR clinical trials? METHODS: We performed a MEDLINE search of the published literature from 1995 to the present. We used appropriate search terms, such as allergic rhinitis, seasonal allergic rhinitis, perennial allergic rhinitis, SAR, and PAR, to identify pertinent articles. These articles were reviewed and graded according to the evidence quality. RESULTS: After an initial screening of more than 300 articles, 138 articles were analyzed thoroughly. No study specifically addressed the question of the optimal duration of SAR or PAR clinical trials. CONCLUSIONS: We conclude that the current FDA (draft) guidelines calling for a study length of 2 weeks for the assessment of drug efficacy for SAR and 4 weeks for the study of drug efficacy in PAR are appropriate and that longer study periods are not likely to add meaningfully to the assessment of drug efficacy.

Original languageEnglish (US)
Pages (from-to)467-487
Number of pages21
JournalOtolaryngology - Head and Neck Surgery
Volume133
Issue number4
DOIs
StatePublished - Oct 2005

Fingerprint

Rhinitis, Allergic, Perennial
Seasonal Allergic Rhinitis
Clinical Trials
United States Food and Drug Administration
Guidelines
Pharmaceutical Preparations
Allergic Rhinitis
MEDLINE
Research Personnel

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Krouse, J. H., Roland, P. S., Marple, B. F., Wall, G. M., Hannley, M., Golla, S., & Hunsaker, D. (2005). Optimal duration of allergic rhinitis clinical trials. Otolaryngology - Head and Neck Surgery, 133(4), 467-487. https://doi.org/10.1016/j.otohns.2005.07.024

Optimal duration of allergic rhinitis clinical trials. / Krouse, John H.; Roland, Peter S.; Marple, Bradley F.; Wall, G. Michael; Hannley, Maureen; Golla, Suman; Hunsaker, Darrell.

In: Otolaryngology - Head and Neck Surgery, Vol. 133, No. 4, 10.2005, p. 467-487.

Research output: Contribution to journalArticle

Krouse, JH, Roland, PS, Marple, BF, Wall, GM, Hannley, M, Golla, S & Hunsaker, D 2005, 'Optimal duration of allergic rhinitis clinical trials', Otolaryngology - Head and Neck Surgery, vol. 133, no. 4, pp. 467-487. https://doi.org/10.1016/j.otohns.2005.07.024
Krouse, John H. ; Roland, Peter S. ; Marple, Bradley F. ; Wall, G. Michael ; Hannley, Maureen ; Golla, Suman ; Hunsaker, Darrell. / Optimal duration of allergic rhinitis clinical trials. In: Otolaryngology - Head and Neck Surgery. 2005 ; Vol. 133, No. 4. pp. 467-487.
@article{befa614fe32e4a629682822c28250cbe,
title = "Optimal duration of allergic rhinitis clinical trials",
abstract = "OBJECTIVE: Guidelines have been published by the Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA) for the conduct of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) studies. These guidelines have differences regarding the duration of such trials: the FDA suggests 2 weeks for SAR and 4 weeks for PAR but the EMEA suggests 2 to 4 weeks for SAR and 6 to 12 weeks for PAR trials. In the interest of global harmonization, it would be desirable to have a uniform duration of such trials so that investigators, internationally, would be able to readily compare results for various types of treatments based on a single standard. Therefore, we performed an evidence-based review to answer the clinical question, What is the optimal duration for SAR and PAR clinical trials? METHODS: We performed a MEDLINE search of the published literature from 1995 to the present. We used appropriate search terms, such as allergic rhinitis, seasonal allergic rhinitis, perennial allergic rhinitis, SAR, and PAR, to identify pertinent articles. These articles were reviewed and graded according to the evidence quality. RESULTS: After an initial screening of more than 300 articles, 138 articles were analyzed thoroughly. No study specifically addressed the question of the optimal duration of SAR or PAR clinical trials. CONCLUSIONS: We conclude that the current FDA (draft) guidelines calling for a study length of 2 weeks for the assessment of drug efficacy for SAR and 4 weeks for the study of drug efficacy in PAR are appropriate and that longer study periods are not likely to add meaningfully to the assessment of drug efficacy.",
author = "Krouse, {John H.} and Roland, {Peter S.} and Marple, {Bradley F.} and Wall, {G. Michael} and Maureen Hannley and Suman Golla and Darrell Hunsaker",
year = "2005",
month = "10",
doi = "10.1016/j.otohns.2005.07.024",
language = "English (US)",
volume = "133",
pages = "467--487",
journal = "Otolaryngology - Head and Neck Surgery (United States)",
issn = "0194-5998",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Optimal duration of allergic rhinitis clinical trials

AU - Krouse, John H.

AU - Roland, Peter S.

AU - Marple, Bradley F.

AU - Wall, G. Michael

AU - Hannley, Maureen

AU - Golla, Suman

AU - Hunsaker, Darrell

PY - 2005/10

Y1 - 2005/10

N2 - OBJECTIVE: Guidelines have been published by the Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA) for the conduct of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) studies. These guidelines have differences regarding the duration of such trials: the FDA suggests 2 weeks for SAR and 4 weeks for PAR but the EMEA suggests 2 to 4 weeks for SAR and 6 to 12 weeks for PAR trials. In the interest of global harmonization, it would be desirable to have a uniform duration of such trials so that investigators, internationally, would be able to readily compare results for various types of treatments based on a single standard. Therefore, we performed an evidence-based review to answer the clinical question, What is the optimal duration for SAR and PAR clinical trials? METHODS: We performed a MEDLINE search of the published literature from 1995 to the present. We used appropriate search terms, such as allergic rhinitis, seasonal allergic rhinitis, perennial allergic rhinitis, SAR, and PAR, to identify pertinent articles. These articles were reviewed and graded according to the evidence quality. RESULTS: After an initial screening of more than 300 articles, 138 articles were analyzed thoroughly. No study specifically addressed the question of the optimal duration of SAR or PAR clinical trials. CONCLUSIONS: We conclude that the current FDA (draft) guidelines calling for a study length of 2 weeks for the assessment of drug efficacy for SAR and 4 weeks for the study of drug efficacy in PAR are appropriate and that longer study periods are not likely to add meaningfully to the assessment of drug efficacy.

AB - OBJECTIVE: Guidelines have been published by the Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA) for the conduct of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) studies. These guidelines have differences regarding the duration of such trials: the FDA suggests 2 weeks for SAR and 4 weeks for PAR but the EMEA suggests 2 to 4 weeks for SAR and 6 to 12 weeks for PAR trials. In the interest of global harmonization, it would be desirable to have a uniform duration of such trials so that investigators, internationally, would be able to readily compare results for various types of treatments based on a single standard. Therefore, we performed an evidence-based review to answer the clinical question, What is the optimal duration for SAR and PAR clinical trials? METHODS: We performed a MEDLINE search of the published literature from 1995 to the present. We used appropriate search terms, such as allergic rhinitis, seasonal allergic rhinitis, perennial allergic rhinitis, SAR, and PAR, to identify pertinent articles. These articles were reviewed and graded according to the evidence quality. RESULTS: After an initial screening of more than 300 articles, 138 articles were analyzed thoroughly. No study specifically addressed the question of the optimal duration of SAR or PAR clinical trials. CONCLUSIONS: We conclude that the current FDA (draft) guidelines calling for a study length of 2 weeks for the assessment of drug efficacy for SAR and 4 weeks for the study of drug efficacy in PAR are appropriate and that longer study periods are not likely to add meaningfully to the assessment of drug efficacy.

UR - http://www.scopus.com/inward/record.url?scp=26444591867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444591867&partnerID=8YFLogxK

U2 - 10.1016/j.otohns.2005.07.024

DO - 10.1016/j.otohns.2005.07.024

M3 - Article

C2 - 16213915

AN - SCOPUS:26444591867

VL - 133

SP - 467

EP - 487

JO - Otolaryngology - Head and Neck Surgery (United States)

JF - Otolaryngology - Head and Neck Surgery (United States)

SN - 0194-5998

IS - 4

ER -